In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on Qiagen NV (NYSE: QGEN), with a price target of $39. The company’s shares closed yesterday at $35.57.
According to TipRanks.com, Beuchaw is a 4-star analyst with an average return of 12.6% and a 64.6% success rate. Beuchaw covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Myriad Genetics, and NanoString Tech.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen NV with a $40.50 average price target, which is a 13.9% upside from current levels. In a report issued on October 5, Deutsche Bank also maintained a Buy rating on the stock with a $44 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.45 and a one-year low of $30.20. Currently, Qiagen NV has an average volume of 878.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
QIAGEN NV is a holding company, which engages in the manufacture and distribution of sample and assay technology products for preanalytical sample preparations. It provides solutions to customers that are classified into molecular diagnostics, applied testing, pharma, and academia. Its products include instruments, and consumables and related products.
